The role of vitamins K and D in the processes of ectopic calcification in patients with chronic kidney disease: The current state of the problem

O.  Susla; O.  Bushtynska; S.  Danyliv; L.  Logoyda; A.  Gozhenko

doi:10.31450/ukrjnd.3(75).2022.09

O. Susla Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України https://orcid.org/0000-0002-1078-5898
O. Bushtynska Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
S. Danyliv Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
L. Logoyda Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
A. Gozhenko ДП «Український науково-дослідний інститут медицини транспорту МОЗ України»

DOI: https://doi.org/10.31450/ukrjnd.3(75).2022.09

Ключові слова: хронічна хвороба нирок, серцево-судинна система, ектопічна кальцифікація, атеросклероз, вітамін К, вітамін D, матриксний Gla-протеїн, остеокальцин, патогенез, лікування.

Анотація

Резюме. Узагальнення експериментальних і клінічних даних дозволяють на сьогодні стверджувати про важливу патогенетичну роль дефіциту вітаміну К у механізмах кардіоваскулярної кальцифікації та атеросклеротичного ушкодження у хворих на хронічну хворобу нирок (ХХН). Підкреслено, що активність та експресія матриксного Gla-протеїну як потужного інгібітора судинної кальцифікації, окрім вітаміну К, суттєво залежить від вітаміну D. Ефективність і безпечність поєднаного застосування добавок вітамінів К і D щодо сповільнення прогресування ектопічної кальцифікації, зменшення серцево-судинного ризику та покращення прогнозу у хворих на ХХН вимагають підтвердження в багатоцентрових рандомізованих контрольованих дослідженнях.

Завантаження

Дані завантаження ще не доступні.

Посилання

Barrett H, O'Keeffe M, Kavanagh E, Walsh M, O'Connor EM. Is Matrix Gla Protein Associated with Vascular Calcification? A Systematic Review. Nutrients. 2018;10(4):415. doi:10.3390/nu10040415.

Ketteler M, Rothe H, Brandenburg VM, Westenfeld R. The K-factor in chronic kidney disease: biomarkers of calcification inhibition and beyond. Nephrol Dial Transplant. 2014;29(7):1267-1270. doi:10.1093/ndt/gfu053.

Ketteler M, Schanz M, Schricker S. Vitamin K: should we supplement to protect the kidneys and the heart? Nephrol Dial Transplant. 2021;36(12):2196-2198. doi:10.1093/ndt/gfz291.

Schurgers LJ. Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease. Kidney Int. 2013;83(5):782-784. doi:10.1038/ki.2013.26.

Hou YC, Lu CL, Zheng CM, Chen RM, Lin YF, Liu WC, et al. Emerging role of vitamins D and K in modulating uremic vascular calcification: The aspect of passive calcification. Nutrients. 2019; 11(1): 152. doi.org/10.3390/nu11010152.

Wasilewski GB, Vervloet MG, Schurgers LJ. The Bone-Vasculature Axis: Calcium Supplementation and the Role of Vitamin K. Front Cardiovasc Med. 2019;6:6. doi:10.3389/fcvm.2019.00006.

Caluwé R, Verbeke F, De Vriese AS. Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients. Nephrol Dial Transplant. 2020;35(1):23-33. doi:10.1093/ndt/gfy373.

Peeters FECM, Dudink EAMP, Kimenai DM, Weijs B, Altintas S, Heckman LIB, et al. Vitamin K Antagonists, Non-Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation. TH Open. 2018;2(4):e391-e398. doi:10.1055/s-0038-1675578.

van Ballegooijen AJ, Beulens JWJ, Keyzer CA, Navis GJ, Berger SP, de Borst MH, et al. Joint association of vitamins D and K status with long-term outcomes in stable kidney transplant recipients. Nephrol Dial Transplant. 2020;35(4):706-714. doi:10.1093/ndt/gfy399.

Garbuzova VYu, Ataman OV. Matrix Gla-protein and its role in vascular wall calcification. Fiziol Zh. 2011;57(4):96-112. Available from: https://pubmed.ncbi.nlm.nih.gov/22167840/.

Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, et al. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant. 2014;29(9):1633-1638. doi:10.1093/ndt/gft459.

Keung L, Perwad F. Vitamin D and kidney disease. Bone Rep. 2018;9:93-100. doi:10.1016/j.bonr.2018.07.002.

Andrukhova O, Slavic S, Zeitz U, Riesen SC, Heppelmann MS, Ambrisko TD, et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol. 2014;28(1):53-64. doi:10.1210/me.2013-1252.

Vila Cuenca M, van Bezu J, Beelen RHJ, Vervloet MG, Hordijk PL. Stabilization of cell-cell junctions by active vitamin D ameliorates uraemia-induced loss of human endothelial barrier function. Nephrol Dial Transplant. 2019;34(2):252-264. doi:10.1093/ndt/gfy111.

Bacchetta J, Pelletier S. Vitamin D deficiency is associated with mortality in maintenance dialysis: moving forward from epidemiology to clinical trials. Nephrol Dial Transplant. 2018;33(10):1679-1682. doi:10.1093/ndt/gfy122.

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674- 2014;27(5):483-94. doi:10.1001/jama.2012.120.

Wang A Y-M, Fang F, Chan J, Wen Y-Y, Oing S, Chan I H-S, et al. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol. 2014;25(1):175-186. doi:10.1681/ASN.2013010103.

Manson JE, Bassuk SS, Buring JE, VITAL Research Group. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol. 2020;198:105522. doi:10.1016/j.jsbmb.2019.105522.

Fusaro M, Tripepi G, Plebani M, Politi C, Aghi A, Taddei F, et al. The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. Nutrients. 2021;13(10):3567. doi:10.3390/nu13103567.

Riphagen IJ, Keyzer CA, Drummen NEA, de Borst MH, Beulens JWJ, Gansevoort RT, et al. Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study. Nutrients. 2017;9(12):1334. doi:10.3390/nu9121334.

De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, et al. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol. 2020;31(1):186-196. doi:10.1681/ASN.2019060579.

Oikonomaki T, Papasotiriou M, Ntrinias T, Kalogeropoulou C, Zabakis P, Kalavrizioti D, et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. Int Urol Nephrol. 2019;51(11):2037-2044. doi:10.1007/s11255-019-02275-2.

Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014;29(7):1385-1390. doi:10.1093/ndt/gft464.

Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59(2):186-195. doi:10.1053/j.ajkd.2011.10.041.

Lee SM, An WS. Supplementary nutrients for prevention of vascular calcification in patients with chronic kidney disease. Korean J Intern Med. 2019;34(3):459-469. doi:10.3904/kjim.2019.125.

Ivanova D, Zhelev Z, Getsov P, Nikolova B, Aoki I, Higashi T, et al. Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect. Redox Biology. 2018;16:352-358. doi:10.1016/j.redox.2018.03.013.

Egshatyan LV, Mokrysheva NG. Ectopic calcification in chronic kidney disease. Part 1. Classification and pathogenesis. Nephrology. 2017;21(4):30-39. doi:10.24884/1561-6274-2017-21-4-30-39.

Yao Y, Jumabay M, Ly A, Radparvar M, Cubberly MR, Boström KI. A role for the endothelium in vascular calcification. Circ Res. 2013;113(5):495-504. doi:10.1161/CIRCRESAHA.113.301792.

Nitta K, Ogawa T, Hanafusa N, Tsuchiya K. Recent Advances in the Management of Vascular Calcification in Patients with End-Stage Renal Disease. Contrib Nephrol. 2019;198:62-72. doi:10.1159/000496532.

Fusaro M, D'Alessandro C, Noale M, Tripepi G, Plebani M, Veeronese N, et al. Low vitamin K1 intake in haemodialysis patients. Clin Nutr. 2017;36(2):601-607. doi:10.1016/j.clnu.2016.04.024.

McCabe KM, Booth SL, Fu X, Ward E, Adams MA, Holden RM. Vitamin K Metabolism in a Rat Model of Chronic Kidney Disease. Am J Nephrol. 2017;45(1):4-13. doi:10.1159/000451068.

Nigwekar SU, Bloch DB, Nazarian RM, Vermeer C, Booth SL, Xu D, et al. Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis. J Am Soc Nephrol. 2017;28(6):1717-1722. doi:10.1681/ASN.2016060651.

Kaesler N, Magdeleyns E, Herfs M, Schettgen T, Brandenburg V, Fliser D, et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int. 2014;86(2):286-293. doi:10.1038/ki.2013.530.

Rattazzi M, Faggin E, Bertacco E, Nardin C, Pagliani L, Plebani M, et al. Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE-/- mice. Cardiovasc Ther. 2018;36(4):e12438. doi:10.1111/1755-5922.12438.

Nigwekar SU, Zhao S, Wenger J, Hymes JL, Maddux FW, Thadhani RI, et al. A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. J Am Soc Nephrol. 2016;27(11):3421-3429. doi:10.1681/ASN.2015091065.

Zaragatski E, Grommes J, Schurgers LJ, Langer S, Kennes L, Tamm M, et al. Vitamin K antagonism aggravates chronic kidney disease-induced neointimal hyperplasia and calcification in arterialized veins: role of vitamin K treatment? Kidney Int. 2016;89(3):601-611. doi:10.1038/ki.2015.298.

Holden RM, Booth SL, Day AG, Clase CM, Zimmerman D, Moist L, et al. Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis. 2015;2:17. doi:10.1186/s40697-015-0053-x.

Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J Nutr. 2004;134(11):3100-3105. doi:10.1093/jn/134.11.3100.

Brandenburg VM, Reinartz S, Kaesler N, Krüger T, Dirrichs T, Kramann R, et al. Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation: Results From a Prospective Interventional Proof-of-Concept Study. Circulation. 2017;135(21):2081-2083. doi:10.1161/CIRCULATIONAHA.116.027011.

Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580-1584. doi:10.1093/ndt/gfr658.

Kodumudi V, Jeha GM, Mydlo N, Kaye AD. Management of Cutaneous Calciphylaxis. Adv Ther. 2020;37(12):4797-4807. doi:10.1007/s12325-020-01504-w.

Brandenburg VM, Kramann R, Rothe H, Kaesler N, Korbiel J, Specht P, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017;32(1):126-132. doi:10.1093/ndt/gfv438.

Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016;31(1):31-39. doi:10.1093/ndt/gfv111.

Fusaro M, Cianciolo G, Brandi ML, Ferrari S, Nickolas TL, Tripepi G, et al. Vitamin K and Osteoporosis. Nutrients. 2020;12(12):3625. doi:10.3390/nu12123625.

Evenepoel P, Claes K, Meijers B, Laurent M, Bammens B, Naesens M, et al. Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. J Bone Miner Res. 2019;34(2):262-269. doi:10.1002/jbmr.3608.

Cui L, Xu J, Zhang J, Zhang M, Zhang S, Bai Y. Menaquinone-4 modulates the expression levels of calcification-associated factors to inhibit calcification of rat aortic vascular smooth muscle cells in a dose-dependent manner. Exp Ther Med. 2018;16(4):3172-3178. doi:10.3892/etm.2018.6535.

Vossen LM, Schurgers LJ, van Varik BJ, Kietselaer BL, Vermeer C, Meeder JG, et al. Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial). Nutrients. 2015;7(11):8905-8915. doi:10.3390/nu7115443.

Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135-1144. doi:10.1160/TH14-08-0675.

Nakagawa K. Diseases Due to the Deficiency in Vitamin K Conversion System and Its Prevention. Yakugaku Zasshi. 2021;141(5):669-674. doi:10.1248/yakushi.20-00243-1.

Haroon SW, Tai BC, Ling LH, Teo L, Davenport A, Schurgers L, et al. Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK): A study protocol for a randomized controlled trial. Medicine (Baltimore). 2020;99(36):e21906. doi:10.1097/MD.0000000000021906.

Levy-Schousboe K, Frimodt-MøllerM, Hansen D, Peters CD, Kjærgaard, Jensen JD, et al. Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. Clin Kidney J. 2021;14(9):2114-2123. doi:10.1093/ckj/sfab017.

Gigante A, Brugè F, Cecconi S, Manzotti S, Littarru GP, Tiano L. D3-induced osteogenesis in hMSCs: Modulation of key effectors in mineralization and vascularization J Tissue Eng Regen Med. 2015;9(6):691-701. doi:10.1002/term.1627.

Poon CC, Li RW, Seto SW, Kong SK, Ho HP, Hoi MPM, et al. In vitro vitamin K(2) and 1α,25-dihydroxyvitamin D(3) combination enhances osteoblasts anabolism of diabetic mice. Eur J Pharmacol. 2015;767:30-40. doi:10.1016/j.ejphar.2015.09.048.

Smirnov AV, Volkov MM, Dobronravov VA. Cardioprotective effects of D-hormone in patients with chronic kidney disease: literature rewiew and personal data. Nephrology. 2009;13(1):30-38.

Legarth C, Grimm D, Wehland M, Bauer J, Krüger M. The Impact of Vitamin D in the Treatment of Essential Hypertension. Int J Mol Sci. 2018;19(2):455. doi:10.3390/ijms19020455.

Murni IK, Sulistyoningrum DC, Oktaria V. Association of vitamin D deficiency with cardiovascular disease risk in children: implications for the Asia Pacific Region. Asia Pac J Clin Nutr. 2016;25(Suppl 1):S8-S19. doi:10.6133/apjcn.122016.s1.

O'Connor E, Mølgaard C, Michaelsen KF, Jakobsen J, Lamberg-Allardt CJ, Cashman KD. Serum percentage undercarboxylated osteocalcin, a sensitive measure of vitamin K status, and its relationship to bone health indices in Danish girls. Br J Nutr. 2007;97(4):661-6. doi:10.1017/S0007114507433050.

Mayer O Jr, Seidlerová J, Wohlfahrt P, Filipovský J, Cífková R, Černá V, et al. Synergistic effect of low K and D vitamin status on arterial stiffness in a general population. J Nutr Biochem. 2017; 46:83-89. doi:10.1016/j.jnutbio.2017.04.010.

Asemi Z, Raygan F, Bahmani F, Rezavandi Z, Talari HR, Rafiee M, et al. The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD. Br J Nutr. 2016;116(2):286-293. doi:10.1017/S0007114516001847.

Sanguineti R, Monacelli F, Parodi A, Furfaro AL, Borghi R, Pacini D, et al. Vitamins D3 and K2 may partially counterbalance the detrimental effects of pentosidine in ex vivo human osteoblasts. J Biol Regul Homeost Agents. 2016;30(3):713-726.

da Silva Canhos MM, de Oliveira RC, Modelli de Andrade LG, Caramori JCT, Barretti P, Martin LC. Association between vitamin D levels and mortality in hemodialysis patients: a cohort study. Ren Fail. 2020;42(1):225-233. doi:10.1080/0886022X.2020.1735415.

Роль вітамінів К і D у процесах ектопічної кальцифікації у хворих на хронічну хворобу нирок: сучасний стан проблеми

Анотація

Завантаження

Посилання